Guilford Gliadel Wafer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
An sNDA for Gliadel (carmustine wafer) will be reviewed by the Oncologic Drugs Advisory Committee Sept. 11 for first-line use to significantly prolong survival and maintain overall function as measured by preservation of Karnofsky performance status and neurologic function in patients with malignant glioma undergoing primary or recurrent surgical resection. The supplemental application was submitted in April and is receiving priority review. Guilford estimates that the first-line indication would triple the potential patient population for the drug from 3,500 to 10,000-12,000. Gliadel currently is approved for recurrent glioblastoma multiforme
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.